logo
welcome
About us
Newsletter
News Widget
Media Inquiries

Summary

2024's Key Medical Breakthroughs

This is a U.S. news story, published by Gizmodo, that relates primarily to Cobenfy news.

U.S. news

For more U.S. news, you can click here:

more U.S. news

Cobenfy news

For more Cobenfy news, you can click here:

more Cobenfy news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Gizmodo news

For more news from Gizmodo, you can click here:

more news from Gizmodo

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

other antibiotics

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest first antibiotic news, Antibiotic resistance news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

antibiotics
Gizmodo

Gizmodo

•

The Biggest Medical Breakthroughs of 2024

Gizmodo
Summary
Nutrition label

81% Informative

Orlynvah is the first antibiotic of its kind, combining a drug that extends the duration of antibiotics in the body with a compound from a subclass of antibacterials known as penems.

Cobenfy , the first truly novel drug for schizophrenia seen since the 1950s , was approved in September .

A vaccine-like barrier against HIV is already approved to treat HIV.

In September , the FDA approved the first -ever medications designed to treat Niemann-Pick disease type C (NPC ) The median life expectancy of sufferers in the U.S. is currently only 13 .

In August , Bayer published the results of two successful Phase III trials testing its experimental drug elinzanetant as a treatment for moderate to severe hot flashes in women over 40 .

VR Score

76

Informative language

75

Neutral language

26

Article tone

semi-formal

Language

English

Language complexity

64

Offensive language

possibly offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

External references

20

https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-niemann-pick-disease-type-chttps://www.pennmedicine.org/news/news-releases/2024/september/improvement-in-sight-seen-after-gene-therapy-trialhttps://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-preventionhttps://www.businesswire.com/news/home/20240730731594/en/Vertex-Announces-FDA-Acceptance-of-New-Drug-Application-for-Suzetrigine-for-the-Treatment-of-Moderate-to-Severe-Acute-Painhttps://www.nature.com/articles/s41573-024-01007-1https://www.stocktitan.net/news/NVAX/novavax-initiates-phase-3-trial-for-covid-19-influenza-combination-8swks19zskon.htmlhttps://www.fda.gov/news-events/press-announcements/fda-approves-novel-drug-treat-moderate-severe-hot-flashes-caused-menopausehttps://www.vax-before-travel.com/2024/09/12/moderna-focuses-influenza-covid-combination-vaccine-candidatehttps://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-niemann-pick-disease-type-chttps://www.science.org/content/article/breakthrough-2024https://rarediseases.org/rare-diseases/niemann-pick-disease-type-c/https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-successful-completion-end-phase-2-meetinghttps://www.healio.com/news/neurology/20241202/miplyffa-commercially-available-for-treatment-of-niemannpick-disease-type-chttps://www.foxnews.com/health/new-brain-therapy-allows-paralyzed-patients-walk-again-feel-legshttps://www.who.int/news/item/26-09-2024-long-acting-injectable-lenacapavir-continues-to-show-promising-results-for-hiv-preventionhttps://www.nature.com/articles/d41573-024-00129-whttps://www.statnews.com/2024/12/11/hiv-prevention-gilead-once-a-year-prep/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112764/https://investors.amgen.com/news-releases/news-release-details/amgen-announces-robust-weight-loss-maritide-people-livinghttps://www.gilead.com/news/news-details/2024/gileads-twice-yearly-lenacapavir-demonstrated-100-efficacy-and-superiority-to-daily-truvada-for-hiv-prevention

Source diversity

16

www.fda.govwww.pennmedicine.orgwww.businesswire.comwww.nature.comwww.stocktitan.netwww.vax-before-travel.comwww.science.orgrarediseases.orgir.altimmune.comwww.healio.comwww.foxnews.comwww.who.intwww.statnews.comwww.ncbi.nlm.nih.govinvestors.amgen.comwww.gilead.com

Affiliate links

no affiliate links

Read full article